These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23836985)

  • 1. Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.
    Zhang Z; Hao C; Wang L; Liu P; Zhao L; Zhu C; Tian X
    Onco Targets Ther; 2013; 6():733-40. PubMed ID: 23836985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reversed effect of valproic acid on transcription inhibition of AML1-ETO fusion protein of kasumi-1 leukemic cell line].
    Zhao L; Zhu CM; Zhang ZH; Tian WL; Hao CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):363-7. PubMed ID: 19379567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
    Berg T; Fliegauf M; Burger J; Staege MS; Liu S; Martinez N; Heidenreich O; Burdach S; Haferlach T; Werner MH; Lübbert M
    Haematologica; 2008 Nov; 93(11):1728-33. PubMed ID: 18790797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
    Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
    Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
    Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    Wang J; Saunthararajah Y; Redner RL; Liu JM
    Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21)-positive Kasumi-1 and primary acute myeloid leukemia cells.
    Hui H; Zhang X; Li H; Liu X; Shen L; Zhu Y; Xu J; Guo Q; Lu N
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1449-59. PubMed ID: 27085528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
    Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
    Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M
    Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.
    Barbetti V; Tusa I; Cipolleschi MG; Rovida E; Dello Sbarba P
    Cell Death Dis; 2013 Mar; 4(3):e536. PubMed ID: 23492767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition.
    Findeisen HM; Gizard F; Zhao Y; Qing H; Heywood EB; Jones KL; Cohn D; Bruemmer D
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):851-60. PubMed ID: 21233448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.